RSVP

Please submit your RSVP HERE

You are invited to join us for an exciting evening to discuss the latest advances to treat thyroid eye disease (TED), including the recently published data regarding Teprotumumab.

Dr. Raymond Douglas, a leading expert in TED and the principal investigator for the Phase 3 trial evaluating Teprotumumab treatment in subjects with active TED (ClinicalTrials.gov NCT03298867), will be discussing the clinical experience with Teprotumumab and also opportunities for patient enrollment in the ongoing international clinical trial. There are limited clinical trial sites within the US, so don’t miss this opportunity to learn about the latest advances in TED and find out if your patients qualify for the teprotumumab clinical trial!

Dinner Information

April 3, 2018 at 6:30 pm

Cafe Del Rey
4451 Admirality Way
Marina Del Rey, CA 90292

 April 11, 2018 at 6:30 pm

Mastro’s Steakhouse

246 N. Canon Drive
Beverly Hills, CA 90210

April 17, 2018 at 6:30 pm

Ruth’s Chris

369 E Colorado Blvd
Pasadena, CA 91101

Please submit your RSVP HERE

If you have any additional questions, please feel free to email us at [email protected]

Investigational Drug May Reduce Graves’ Eye Disease Symptoms

Teprotumumab was granted Breakthrough Therapy Designation by the US FDA; a process designed to expedite the review of drugs intended to treat a serious condition for which preliminary clinical evidence demonstrates improvement over available therapy on a clinically significant endpoint.

“Teprotumumab for Thyroid-Associated Ophthalmopathy”

 

Thyroid Eye Disease is a difficult and vexing disease and Teprotumumab has shown promise in the phase 2 trial. “Teprotumumab for Thyroid-Associated Ophthalmopathy” was recently published in the New England Journal of Medicine. For those that suffer with bulging of the eyes due to Thyroid Eye Disease, Teprotumumab is the first investigational drug of its kind that may provide a therapy to reduce eye bulging.  The Teprotumumab group achieved reduced eye bulging, clinical activity, double vision and improved quality of life compared to placebo in the phase 2 study.

Call Our Office Today

(310) 657-4302

Send Us a Message

  • This field is for validation purposes and should be left unchanged.